Related Experiment Videos
Exogenous surfactant therapy in newborns
1Division of Neonatology, Department of Pediatrics, Rainbow Babies and Children's Hospital, University Hospitals of Cleveland, Ohio 44106, USA.
Insights
Surfactant replacement therapy significantly improves neonatal intensive care for premature infants with respiratory distress syndrome (RDS). Further research explores its role in other neonatal respiratory conditions.
Area of Science:
- Neonatal Intensive Care
- Pulmonology
- Biochemistry
Background:
- Respiratory distress syndrome (RDS) is a significant challenge in premature infants.
- Surfactant replacement therapy has revolutionized RDS management.
- The impact of surfactant therapy on chronic lung disease remains unclear.
Purpose of the Study:
- To provide an overview of the surfactant system's physiology.
- To discuss current applications of surfactant therapy in newborns.
- To explore emerging uses and challenges in neonatal respiratory disorders.
Main Methods:
- Literature review of surfactant physiology and therapy.
- Analysis of clinical outcomes in neonatal respiratory conditions.
- Discussion of surfactant inactivation in neonatal lung disease.
Main Results:
- Surfactant therapy is a major advance in neonatal intensive care for RDS.
- The effect on chronic lung disease incidence requires further investigation.
- Surfactant inactivation plays a role in meconium aspiration syndrome and pneumonia.
Conclusions:
- Surfactant therapy has transformed the care of premature infants with RDS.
- New applications and challenges are emerging for surfactant therapy in neonates.
- Understanding surfactant physiology is crucial for managing neonatal respiratory disorders.
Abstract:
The introduction of surfactant replacement therapy for the management of respiratory distress syndrome (RDS) in the premature infant is one of the major advances in neonatal intensive care. After almost 50 years of intense research, the concerted efforts of basic scientists and clinicians have been rewarded. Despite the remarkable effects of surfactant therapy of RDS, the impact on the incidence of chronic lung disease has been unclear. With the recognition of the role of surfactant inactivation in the pathogenesis of other respiratory disorders of newborns (i.e., meconium aspiration syndrome and pneumonia) newer applications as well as new challenges have emerged. This article provides an overview of the physiology of the surfactant system and the current uses of this therapy in newborns.